Cita APA (7a ed.)
(2025 Supplement). Dual-Targeted Therapy With Risankizumab and Upadacitinib Is Clinically and Biochemically Effective in Medically Complex CD. Gastroenterology & Hepatology, 21, 15-17.
Cita Chicago Style (17a ed.)
"Dual-Targeted Therapy With Risankizumab and Upadacitinib Is Clinically and Biochemically Effective in Medically Complex CD." Gastroenterology & Hepatology 21 (2025 Supplement): 15-17.
Cita MLA (9a ed.)
"Dual-Targeted Therapy With Risankizumab and Upadacitinib Is Clinically and Biochemically Effective in Medically Complex CD." Gastroenterology & Hepatology, vol. 21, 2025 Supplement, pp. 15-17.
Precaución: Estas citas no son 100% exactas.